ArticleThe Journal of antimicrobial chemotherapy2026
Clinical and immunovirological status in children, adolescents and young adults with early-life-acquired HIV: a Spanish multi-cohort analysis since 2020.
Article in The Journal of antimicrobial chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
objectivesART has significantly improved survival among children, adolescents and young adults who acquired HIV perinatally or during early childhood (early-life acquired HIV, ELHIV). However, challenges persist, including virological failure (VF) and suboptimal immune recovery. This study aimed to describe clinical, virological and immunological outcomes of ELHIV individuals in Spain since 2020, and to identify factors associated with VF and impaired immune recovery.
methodsA multicentre, retrospective cohort study was conducted using data from 642 ELHIV individuals actively followed in the CoRISpe and CoRISpe-FARO cohorts. Data included demographics, ART history, virological suppression (viral load ≤50 copies/mL), CD4/CD8 ratio and CDC immunological categories. Logistic regression identified factors influencing VF and immune progression.
resultsThe median age of participants was 24 years, with 67.6% aged ≥18. Most (93.6%) acquired HIV via vertical transmission, with ART initiated at a median age of 1.93 years. At the time of analysis, 99.1% were on ART. Although 81.1% achieved virological suppression, 10.5% experienced VF, associated with PI-based regimens, independent of age, and a lower CD4 nadir. Immune recovery, defined as a CD4/CD8 ratio ≥1, was achieved by 52.3%. Impaired recovery was linked to older age at ART initiation and lower CD4 nadir, particularly among adolescents (12-18 years) and young adults. Children (<12 years) showed better immune profiles, with 97.8% achieving CD4 counts ≥500 cells/mm³.
conclusionsEarly ART initiation and tailored interventions are essential to optimize outcomes in ELHIV populations. PI-based regimens were a risk factor for VF, whereas integrase strand transfer inhibitors appeared protective. Adolescents and young adults require targeted support to improve adherence and immune recovery, aligning with UNAIDS goals.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.